B2B series webinar:
Intellectual Property and Technology Transfer
On-demand Event
(on-demand access for the webinar series)
This webinar is part of a series of three educational events hosted in advance of the 2021 ARVO Bench to Bedside (B2B) Meeting. The other webinars included in the series are:
Series cost: Free for members
(includes on-demand access for all three webinars)
Description
Intellectual property is intrinsically related to the successful venture of new businesses. The protection of intellectual property through patents is often misunderstood, undervalued and overlooked by bench scientists and innovators. Many times, the scientist/innovator transfers the know-how surrounding a particular invention to a larger institution, but isn’t clear how this act benefits them in the long run.
Featuring a panel of scientists and experts in patent law and tech transfer, this webinar will help scientists, and particularly those in the business of preventing blindness, to develop win-win strategies for technology transfer and patent protection.
Moderator
Justin Koepsel, PhD
Chief of Staff, Vyriad
Justin Koepsel is the chief of staff for Vyriad, Inc. In this role, he is responsible for assisting execution of Vyriad’s strategy and vision include management of strategic planning and budgeting, personnel hiring and career development planning, strategies for access to capital, corporate partnerships and intellectual property. Prior to joining Vyriad in 2020, Koepsel worked at Mayo Clinic Ventures as a technology development manager. He was responsible for seeking out innovative technologies within the institution and facilitating their development and commercialization paths using Ventures’ intellectual property specialists and licensing colleagues as well as interactions with clinical staff, companies, entrepreneurs and investors.
Speakers
Randolph Glickman, PhD
Professor, Department of Ophthalmology
Graduate School of Biomedical Sciences
The University of Texas Health Science Center at San Antonio
Randolph Glickman, professor in the Department of Ophthalmology at The University of Texas Health Science Center at San Antonio, is the author of numerous journal articles, technical reports and conference proceedings. He is a recognized authority on laser-tissue interaction, biomedical optics and nanobiotechnology. In his university research, Glickman and collaborators developed an all-optical detector for ultrasound and photoacoustic imaging and sensing applications, later forming a startup company, EchoLase, Inc., to commercialize this technology. Through the startup process, he gained extensive experience in negotiating IP rights with his home university to enable tech transfer to EchoLase.
Ashwath Jayagopal, PhD
Executive Director of Discovery Medicine
Kodiak Sciences
Ashwath Jayagopal is the executive director of discovery medicine at Kodiak Sciences. Before this position, he was principal investigator at Vanderbilt Eye Institute and head of molecular pharmacology and biomarkers at Roche Pharma Research and Early Development.
Andrew Roberts, JD
Registered Patent Attorney
Organizer
Cheryl Rowe-Rendleman, PhD
CEO and Managing Consultant, Omar Consulting Group LLC
Dr. Cheryl Rowe-Rendleman is a clinical research and development professional, serving as CEO and Managing Consultant of Omar Consulting Group, LLC (Princeton NJ ǀ Durham, NC). Omar (ophthalmic management and research) is a practice that specializes in regulatory and clinical consulting for drugs and devices in the US, Europe, and China. Cheryl attended public school in Baltimore, Maryland and graduated from Princeton University where she studied chemical engineering and biology with a focus in neuroscience. Cheryl completed 2 postdoctoral training fellowships in developmental and degenerative eye diseases at respectively, the University of Texas and the University of San Francisco Medical Schools. She worked in industry for 13 years where she was responsible for driving research and development for different types of drugs and devices that treat diseases including those that cause blindness. She was named co-inventor on 3 US patents in ophthalmic drug delivery, has been involved in over 50 clinical trials, and published numerous manuscripts and books.
